Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IMMU
Previous Symbol
CUSIP45290710
Phone973-605-8200
Debt
Debt-to-Equity Ratio0.05
Current Ratio14.83
Quick Ratio14.83
Price-To-Earnings
Trailing P/E Ratio-22.23
Forward P/E Ratio-21.06
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.16 million
Price / Sales1,985.07
Cash FlowN/A
Price / CashN/A
Book Value$2.39 per share
Price / Book9.60
Profitability
EPS (Most Recent Fiscal Year)($1.03)
Net Income$-273,830,000.00
Net Margins-12,701.21%
Return on Equity-124.54%
Return on Assets-38.70%
Miscellaneous
Employees185
Outstanding Shares186,830,000
Market Cap$4.47 billion
OptionableN/A
Immunomedics (NASDAQ:IMMU) Frequently Asked Questions
What is Immunomedics' stock symbol?
Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."
How were Immunomedics' earnings last quarter?
Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings data on Thursday, August, 23rd. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.46. The biopharmaceutical company earned $0.40 million during the quarter, compared to the consensus estimate of $4.27 million. Immunomedics had a negative net margin of 12,701.21% and a negative return on equity of 124.54%. The business's revenue was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.48) EPS. View Immunomedics' Earnings History.
When is Immunomedics' next earnings date?
What price target have analysts set for IMMU?
6 Wall Street analysts have issued 1-year target prices for Immunomedics' stock. Their forecasts range from $27.00 to $55.00. On average, they anticipate Immunomedics' stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 65.6% from the stock's current price. View Analyst Price Targets for Immunomedics.
What is the consensus analysts' recommendation for Immunomedics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.
Are investors shorting Immunomedics?
Immunomedics saw a increase in short interest in September. As of September 28th, there was short interest totalling 19,884,011 shares, an increase of 10.9% from the September 14th total of 17,928,831 shares. Based on an average daily trading volume, of 1,727,201 shares, the days-to-cover ratio is currently 11.5 days. Approximately 11.9% of the company's stock are short sold. View Immunomedics' Current Options Chain.
Who are some of Immunomedics' key competitors?
Some companies that are related to Immunomedics include IPSEN S A/S (IPSEY), Myriad Genetics (MYGN), Neogen (NEOG), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Vermillion (VRML) and Riot Blockchain (RIOT).
Who are Immunomedics' key executives?
Immunomedics' management team includes the folowing people:
- Mr. Michael R. Garone, VP of Fin. (Age 59)
- Mr. Michael F. Pehl, Pres, CEO & Director (Age 53)
- Mr. Usama Malik, Interim CFO & Principal Financial Officer (Age 43)
- Mr. William Fricker, Principal Accounting Officer, Exec. Director & Corp. Controller (Age 54)
- Ms. Phyllis Parker, Director of Admin.
Who are Immunomedics' major shareholders?
Immunomedics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Seven Eight Capital LP (0.05%), Strs Ohio (0.04%) and Deprince Race & Zollo Inc. (0.01%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.
Which major investors are selling Immunomedics stock?
IMMU stock was sold by a variety of institutional investors in the last quarter, including Seven Eight Capital LP. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison and David M Goldenberg. View Insider Buying and Selling for Immunomedics.
Which major investors are buying Immunomedics stock?
IMMU stock was acquired by a variety of institutional investors in the last quarter, including Deprince Race & Zollo Inc. and Strs Ohio. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.
How do I buy shares of Immunomedics?
Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immunomedics' stock price today?
One share of IMMU stock can currently be purchased for approximately $22.95.
How big of a company is Immunomedics?
Immunomedics has a market capitalization of $4.47 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 185 workers across the globe.
What is Immunomedics' official website?
How can I contact Immunomedics?
Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]
MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
